Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Leal Therapeutics

Request full access

Developing novel therapeutics for patients with major disorders of the central nervous system

United StatesFounded 2021Biotech & Life Sciences

About Leal Therapeutics

Leal Therapeutics is a biotechnology company focused on developing innovative therapies for central nervous system (CNS) disorders. The company operates in the biopharmaceutical market, targeting conditions such as Alzheimer's, Parkinson's, and other neurodegenerative diseases. Leal Therapeutics serves patients, healthcare providers, and research institutions by advancing its proprietary drug candidates through clinical trials. The business model is based on research and development (R&D) and strategic partnerships, generating revenue through licensing agreements, milestone payments, and eventual product sales. The company leverages the extensive academic and industry experience of its leadership team, including founders with successful track records in biotech startups and acquisitions. Leal Therapeutics aims to address unmet medical needs by translating cutting-edge science into effective treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
34
Open positions
None listed
Dealroom signal
87.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Aug 2025 $30M $225M OrbiMed · Euclidean Capital · Dementia Discovery Fund · Alexandria Venture Investments ↗
EARLY VCOther financing Oct 2024 $45M $180M OrbiMed · Euclidean Capital · PhiFund Ventures · Alexandria Venture Investments ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Leal Therapeutics website traffic

Latest recorded traffic for Leal Therapeutics is 3.1K monthly website visits, up 34.8% over the last three months. Leal Therapeutics's team grew 6.3% over the past year.

Latest monthly visits3.1K 3-month web change+34.8% 1-year team growth+6.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Leal Therapeutics in its local ecosystem

Live from Dealroom

The Leal Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A5 investors entered at this stage

  • Newpath Partners
  • Euclidean Capital
  • Alexandria Venture Investments
  • Chugai Venture Fund
  • Dementia Discovery Fund
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States89.7%
🇬🇧 United Kingdom6.9%
🏳️ Togo3.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Leal Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Leal Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.